Navigation Links
A quantum leap in gene therapy of Duchenne muscular dystrophy
Date:1/15/2013

COLUMBIA, Mo.-- Usually, results from a new study help scientists inch their way toward an answer whether they are battling a health problem or are on the verge of a technological breakthrough. Once in a while, those results give them a giant leap forward. In a preliminary study in a canine model of Duchenne muscular dystrophy (DMD), University of Missouri scientists showed exactly such a leap using gene therapy to treat muscular dystrophy. The results of the study will be published in the journal Molecular Therapy on Jan. 15, 2013.

Muscular dystrophy occurs when damaged muscle tissue is replaced with fibrous, bony or fatty tissue and loses function. Duchenne muscular dystrophy is the most common type of muscular dystrophy predominantly affecting boys. Patients with DMD have a gene mutation that disrupts the production of dystrophin, a protein essential for muscle cell survival and function. Absence of dystrophin starts a chain reaction that eventually leads to muscle cell degeneration and death. For years, scientists have been working to find the key to restoring dystrophin, but they have faced many challenges.

One of the largest hurdles in DMD gene therapy is the large size of the gene. Dystrophin is the largest gene in the human genome, containing approximately 4,000 amino acids. To fit the dystrophin gene into a vehicle that could deliver the gene to the appropriate site in the body, one has to delete 70 percent of the gene. The highly abbreviated gene is known as the "micro-dystrophin" gene. Previous studies suggest that micro-dystrophin can effectively stop muscle disease in mice that are missing dystrophin. However, mice that are missing dystrophin show minimal DMD symptoms, and results from mice often do not predict what will happen in humans. In contrast to mice, loss of dystrophin results in severe muscular dystrophy in dogs. If micro-dystrophin can work in dystrophic dogs, it will likely work in human patients. Unfortunately, when micro-dystrophin was tested in dogs in previous studies, it was not successful.

To overcome these hurdles, a team led by Dongsheng Duan, the Margaret Proctor Mulligan Professor in Medical Research at the MU School of Medicine, engineered a new micro-dystrophin gene that carries an important functional region missing in previously tested micro-dystrophins.

"We placed the new microgene into a virus and then injected the virus into dystrophic dogs' muscles," Duan said. Following gene therapy, Duan's team examined the dogs for signs of muscle disease and measured muscle force in treated and untreated dogs. After careful evaluation of 22 dogs, Duan and colleagues found that the new version of micro-dystrophin not only reduced inflammation and fibrosis, it also effectively improved muscle strength.

"This is the first time that we have seen positive gene therapy results in large mammals of DMD," said Duan. "We still have a lot of work to do, but we now know that our gene therapy strategy works in large mammals; this is a quantum leap forward in fighting this disease. Our next step is to test our strategy in a large group of muscles in the dogs, and then, eventually, see if 'whole body therapy' will work in the dogs. We are still a long way off before we will have a human treatment, but with this finding, I do see a light at the end of this tunnel."

If additional studies, including animal studies, are successful within the next few years, MU officials would request authority from the federal government to begin human drug development (this is commonly referred to as the "investigative new drug" status). After this status has been granted, researchers may conduct human clinical trials with the hope of developing new treatments for Duchenne muscular dystrophy.


'/>"/>

Contact: Christian Basi
BasiC@missouri.edu
573-882-4430
University of Missouri-Columbia
Source:Eurekalert  

Related medicine news :

1. Physical therapy in the intensive care unit benefits hospitals bottom line
2. CoachingWebsites and TherapySites Announces Partnership with the Academy of Choice to Offer Website Marketing for Coaches and Therapists
3. Immunotherapy reduces allergic patients sensitivity to peanuts
4. Declining access to electroconvulsive therapy: A clinical choice or an economic one?
5. Therapy Richmond VA 'Best of the Best' Awarded to Good Neighbor Community Services by Follow Media Consulting, Inc.
6. Drug-resistant melanoma tumors shrink when therapy is interrupted
7. Lung cancer patients live longer if they use beta-blockers while receiving radiotherapy
8. Cheap and easy technique to snip DNA could revolutionize gene therapy
9. Sublingual immunotherapy shows promise as treatment for peanut allergy
10. Peanut therapy shows promise in treating peanut allergy
11. Elsevier selected to publish Cytotherapy: The Journal of Cell Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A quantum leap in gene therapy of Duchenne muscular dystrophy
(Date:12/7/2016)... PRUSSIA, PA (PRWEB) , ... December 07, 2016 , ... ... trials with the announcement that it is one of the early adopters completing EU-U.S. ... Shield Framework is designed to provide companies on both sides of the Atlantic with ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Today, ... the most comprehensive mental health systems reform legislation in more than fifty years. ... and the commitment of our elected officials to improving mental health services and ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... their bodies, a researcher at the Icahn School of Medicine at Mount Sinai ... study found that when young children are exposed to secondhand marijuana smoke, measurable ...
(Date:12/7/2016)... CITY, UTAH (PRWEB) , ... December 07, 2016 ... ... today announced the release of Smart Device Remote Control through a new partnership ... across all platforms and strengthens its mobile solutions to help businesses maximize their ...
(Date:12/7/2016)... Georgia (PRWEB) , ... December ... ... today it has acquired Presence Technology, S.L. (“Presence”) for a purchase price ... price adjustments and other considerations. Presence’s annual revenue is approximately $13.2 million. ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016 KEY FINDINGS ... share of the market in 2016 and is expected ... be attributed to a large number of surgical procedures ... the largest share in the patient temperature management market.) ... as reducing loss of blood during surgeries, lowering the ...
(Date:12/8/2016)... 8, 2016 Research and Markets has announced the addition ... their offering. ... This report analyzes the worldwide markets for Endodontic Supplies in US$ ... , Japan , Europe , ... World. Annual estimates and forecasts are provided for the period 2015 ...
(Date:12/8/2016)... QUEBEC CITY , Dec. 8, 2016 /PRNewswire/ ... key US patents for improving the accuracy, reproducibility ... CD images in long and small bone orthopaedic ... proprietary approach to creating personalized orthopaedic restorations based ... create personalized orthopaedic restorations, the company harnesses the ...
Breaking Medicine Technology: